EI
ORIC icon

EAM Investors’s Oric Pharmaceuticals ORIC Stock Holding History

EAM Investors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-190,455
Closed -$1.09M – 336
2023
Q1 		$1.09M Hold
190,455
– – 0.21% 222
2022
Q4 		$1.12M Buy
+190,455
New +$643K 0.23% 206

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors's ORIC Position: Q2 2023 in Review

EAM Investors sold out of Oric Pharmaceuticals (ORIC) in Q2 2023, closing a stake of 190,455 shares — an estimated $1.09M sold.

EAM Investors first reported a position in ORIC in Q4 2022 and held it in 2 quarters. The position peaked at $1.12M in Q4 2022. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2023.

  • EAM Investors reported no remaining Oric Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • EAM Investors sold 190,455 Oric Pharmaceuticals shares in Q2 2023, an estimated $1.09M.
  • EAM Investors first reported a position in Oric Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • EAM Investors's Oric Pharmaceuticals position peaked at $1.12M in Q4 2022.
  • 83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.